Pneumonitis induced by methotrexate in a patient with seronegative rheumatoid arthritis.

Certolizumab Pegol is a pegylated anti-TNF drug without an Fc fragment. PEGylation involves the addition of polyethylene glycol as a ‘transporter’, which gives advantages from the pharmacokinetic point of view.10,11 This could explain its effectiveness when other anti-TNF drugs have failed. Uveitis is a condition that can have serious consequences. Therefore, the capacity to use a new drug for treatment is very encouraging. Although studies are needed to confirm efficacy and safety, the therapeutic response in this patient suggests that certolizumab pegol could be an effective therapeutic alternative for these patients.